GlassScriptPhysician profile
Monil Shah
NPI 1831578319
$4,126.00
in general payments reported to CMS, 2019-2025
24 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $841 · 2021: $480 · 2022: $851 · 2023: $499 · 2024: $547 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,448.62 | 2019-2024 | Jot Dx, Tendril, Coroflow |
| Boston Scientific Corporation | $402.21 | 2021-2025 | Accolade Sr, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $330.18 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $235.64 | 2020 | |
| Chiesi USA, INC. | $233.59 | 2019-2022 | |
| Amgen INC. | $203.69 | 2021-2025 | Repatha, Repatha |
| Medtronic, INC. | $196.08 | 2022-2024 | Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $176.05 | 2019-2022 | |
| Abiomed | $149.37 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $140.50 | 2020-2025 | Eliquis |
| Astellas Pharma US INC | $92.98 | 2019 | |
| Terumo Medical Corporation | $84.95 | 2021 | |
| Pfizer INC. | $78.10 | 2023-2025 | |
| Vifor Pharma, INC. | $46.29 | 2020 | |
| Novartis Pharmaceuticals Corporation | $46.17 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.22 | 2023 | Verquvo, Belsomra |
| Novo Nordisk INC | $34.29 | 2022-2025 | Wegovy |
| Bridgebio Pharma, INC. | $32.03 | 2025 | Attruby |
| Portola Pharmaceuticals, LLC | $31.63 | 2019-2020 | |
| Emd Serono, INC. | $26.91 | 2024 | |
| Atricure, INC. | $25.78 | 2023 | |
| Cardiva Medical, INC. | $25.55 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.75 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $22.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monil Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.